Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2015-02-17 Earnings Release
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Presentation of fourth quarter and preliminary full year 2014 results
Earnings Release Classification · 95% confidence The document text explicitly states it is an invitation to a 'Presentation of fourth quarter and preliminary full year 2014 results' scheduled for February 24, 2015. This announcement serves to inform stakeholders about the upcoming release and presentation of financial results for a specific period (Q4 and preliminary FY 2014). This fits the definition of an Earnings Release (ER) as it announces the results, or potentially a Report Publication Announcement (RPA) if it were only announcing the availability of a separate document. Given the context of presenting results, ER is a strong candidate. However, since the document itself is an invitation to a presentation *of* the results, and not the results highlights themselves (ER) or the full transcript (CT), it is most accurately classified as an announcement related to the release of financial performance data. Since it is announcing the presentation of results, and the document is very short (779 chars), it strongly aligns with the intent of an Earnings Release announcement or a general announcement about financial reporting. Given the options, 'ER' (Earnings Release) is the most appropriate fit for an announcement detailing when and where preliminary quarterly/annual results will be presented, even if it's not the full release document itself. If the document were the actual presentation slides, it would be 'IP'. If it were the transcript, 'CT'. As an announcement of the presentation of results, ER is the best fit among the primary financial reporting codes. Q4 2014
2015-02-17 English
PCI Biotech: Capital increase registered and listing of new shares
Share Issue/Capital Change Classification · 98% confidence The document explicitly discusses a 'Capital increase registered and listing of new shares' resulting from a 'fully underwritten rights issue'. This action directly relates to changes in the company's capital structure and financing activities. Reviewing the definitions, the 'Capital/Financing Update' (CAP) category is the most appropriate fit, as it covers 'Updates on company fundraising, financing activities, or capital structure changes.' Although it mentions the completion of a process, the core subject is the capital change itself, not just an announcement of a report (RPA) or a general regulatory filing (RNS).
2015-02-12 English
Flagging
Major Shareholding Notification Classification · 98% confidence The document text is very short (724 characters) and details the allocation/granting of shares to related parties (Fondsavanse AS, Erik Must, Fondsformidling AS) and the resulting total shareholding, which crosses a threshold (14.13% of share capital). This pattern strongly indicates a notification regarding a change in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). It is not a full report, a dividend notice, or a director's dealing (as it focuses on related entities' holdings post-granting, not just director transactions).
2015-02-06 Norwegian
Flagging
Share Issue/Capital Change Classification · 99% confidence The document text is very short (276 characters) and reports a specific transaction: MP Pensjon Pk was awarded 520,033 shares in PCI Biotech Holding ASA, resulting in a total holding of 6.11% of the share capital. This describes a change in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification (MRQ). It is not a full report, a management change, or a dividend announcement.
2015-02-06 Norwegian
PCI Biotech: Final results of the rights issue
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly discusses the 'Final results of the rights issue' for PCI Biotech Holding ASA. It details the subscription period, the total number of shares subscribed for, the final allocation of the 7,000,000 new shares offered, the expected payment date, and the resulting capital structure changes. This content directly relates to fundraising, financing activities, and capital structure changes, which aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific corporate financing event.
2015-02-06 English
PCI Biotech: Successful completion of the second dose cohort in the study for patients with inoperable bile duct cancer
Regulatory Filings Classification · 95% confidence The document is a press release dated February 6, 2015, announcing the successful completion of a dose cohort in a Phase I/II clinical study for a cancer treatment (Amphinex®). It details clinical progress, committee recommendations, and provides background information on the disease and the company (PCI Biotech). This type of announcement, focusing on operational and clinical milestones rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), typically falls under general regulatory announcements or investor relations updates. Since it is a specific operational update that doesn't fit perfectly into ER, IR, or CAP, and it is a formal announcement, the most appropriate general category for non-standard, timely corporate news is Regulatory Filings (RNS), which serves as a broad category for such disclosures, especially those mandated by local securities laws (as indicated by the final sentence referencing the Norwegian Securities Trading Act). Given the content is a specific operational update, RNS is the best fit among the provided options.
2015-02-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.